Table 1 Cohort characteristics

From: Dynamics of inflammation resolution and symptom recovery during AECOPD treatment

Characteristics

 

Male (%)

83 (89.2)

Age, years

67 (61,74)

Current smokers (%)

21 (22.6%)

Pack years

25 (22,34)

Duration of COPD, years

6 (5,9)

Cor pulmonale (%)

31 (33.3)

FEV1 (% pred)

47 (43,55)

Frequency of exacerbation in previous year

 

 ≥2

44 (47.3)

 <2

49 (52.7)

BMI (kg/m2)

21.6 (19.0,25.7)

Comorbidities

 

 Arterial hypertension

30 (32.3)

 Ischemic heart disease

20 (21.5)

 Diabetes

13 (14.0)

 Congestive heart failure

13 (14.0)

 Renal disease

7 (7.5)

Pre-admission therapy

 

 Chronic oxygen therapy

21 (22.6)

 Steroid treatment

 

  long-term ICS treatmentΔ

43 (46.2)

  long-term corticosteroid use*

7 (7.5)

Anthonisen type

 

 Type I

62 (66.7)

 Type II–III

31 (33.3)

Cold symptom at presentation

21 (22.6)

  1. Data are presented as median (interquartile ranges) for numerical variables or as number (%) for categorical variables.
  2. FEV1: forced expiratory volume in 1 sec; COPD: Chronic Obstructive Pulmonary Disease; AECOPD: Acute Exacerbations of COPD. Δequivalent to Fluticasone Propionate (FP) ≥ 500 ug/day for more than 1 year. *oral corticosteroids on a regular basis (more than three months treatment with 7.5 mg per day on prednisone or equivalent).
Back to article page